Citations

Clear

1434 citation(s) found for "Le, Nathan".

Abstract 7935: Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial
Fonkoua, Lionel Aurelien Kankeu, Hallemeier, Christopher L., Salem, Basim, Tkachuk, Arina , McCay, Kaitlynn, Wang, Panwen , Li, Ying, Atwell, Thomas D. , Krishan, Jethwa, Tran, Nguyen H., Washburn, Leslie, Wu, Melody Cai‐Syaun, Wu, Chen , Corraes, Andre De Menezes Silva , Graham, Rondell, Villasboas, Jose Caetano, Regan, Kevin M., Shao, Zuoyi, Kamal, Rayaan, Foster, Nathan R. , Dong, Haidong, Park, Sean S., Lin, Yi, Roberts, Lewis R. , Roberts, Lewis R , Fonkoua, Lionel Aurelien Kankeu , Hallemeier, Christopher Leigh , Conboy, Caitlin B.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7935-7935

10.1158/1538-7445.am2026-7935 Get It

Abstract Background: Hepatocellular carcinoma (HCC) is largely refractory to immune checkpoint blockade due to immune exclusion, stromal barriers, and aberrant vasculature. We evaluated whether multimodal therapy - external beam radiotherapy (EBRT) for antigen release, intratumoral dendritic cell (DC) vaccination for antigen presentation, PD-L1 blockade for immune activation, and VEGF inhibition for vascular normalization - could convert “cold” HCC tumors into sustained immune-inflamed states. Methods: Serial biopsies (baseline, post-EBRT, end-of-treatment [EOT], and progression [PD] when available) from three patients enrolled in an ongoing phase II trial (NCT03942328) underwent multiplex immunofluorescence, spatial neighborhood analysis, and transcriptomic profiling. Longitudinal changes in cellular composition, immune-stromal architecture, spatial contact networks, and pathway activity were compared. Results: Baseline tumor microenvironments (TMEs) were strongly immune-excluded, dominated by tumor (PanCK+60-70%) and stroma (SMA+/Vimentin+25-30%) with sparse immune infiltration (<10-15%). Post-therapy, immune complexity and spatial connectivity increased 2-3-fold in all patients. Patient 1 showed robust cold-to-hot conversion with CD8+(3x), CD4+(2.2x), and DC (2.3x) expansion, increased CD8-DC interactions (2.5x), and reduced tumor fraction (-40%). Transcriptomics showed marked upregulation of IFN-γ (↑3.4x), HLA-DRA (↑2.7x), and reductions in VEGFR2 (↓50%) and HIF1A (↓40%), consistent with vascular normalization. Patient 2 exhibited stromal/vascular remodeling and improved T-cell infiltration but restricted immune diversity, with CD4+/CD8+ dyads (↑2.2x) and B/NK cells(↓ 60%). Neighborhood diversity rose (3→7 communities) and immune-tumor proximity improved (distance ↓ 35%). Patient 3 showed transient inflaming with CD8+(↑3x), DC(↑2x), and new CD4-CD20/CD4-CD56 interactions, followed by relapse marked by stromal/myeloid re-expansion (SMA+↑1.8x, CD14+↑2.5x), angiogenic resurgence (VEGFR2/CD34+↑2.2x), contraction of immune networks, and genomic shift from activating CTNNB1 mutation loss to ATM gain. DCs accumulated but localized mainly to DC-DC or DC-myeloid niches, indicating non-productive antigen presentation. Conclusions: Multimodal EBRT+DC+PD-L1/VEGF blockade induces four-sided synergistic TME reprogramming - antigen release, immune priming, checkpoint release, and vascular normalization - promoting cold-to-hot conversion in HCC. Durable inflaming correlates with sustained T-cell/DC expansion and vascular remodeling, whereas relapse reflects stromal/myeloid reinforcement and genomic adaptation. These findings define mechanistic trajectories of TME remodeling and highlight actionable barriers to sustained immunotherapy response in HCC. Citation Format: Lionel Aurelien Kankeu Fonkoua, Christopher L. Hallemeier, Basim Salem, Arina Tkachuk, Kaitlynn McCay, Panwen Wang, Ying Li, Thomas D. Atwell, Krishan R. Jethwa, Caitlin Conboy, Nguyen H. Tran, Leslie A. Washburn, Melody Wu, Chen Wu, Andre De Menezes Silva Corraes, Rondell P. Graham, Jose Caetano Villasboas, Kevin Regan, Zuoyi Shao, Rayaan Kamal, Nathan R. Foster, Haidong Dong, Sean Park, Yi Lin, Lewis R. Roberts. Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7935.
Abstract 7124: Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy
Yee, Shelby K., Carlson, Danielle M. , Ozmert, Enis H., Nishi, Hidemi , Jessen, Erik , Mun, Dong-Gi, Abeynayake, Aushinie, Abdelrahman, Amro , Werneburg, Nathan W., Li, B. , Truty, Mark J. , Ilyas, Sumera, Gores, Gregory J., Smoot, Rory L., Kuipers, Hendrien , Carlson, Danielle Marie , Sample, Jack W. , Mun, Dong‐Gi , Tomlinson, Jennifer L. , Borad, Mitesh J. , Ilyas, Sumera I. , Gores, Gregory J. , Smoot, Rory L.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7124-7124

10.1158/1538-7445.am2026-7124 Get It

Abstract Introduction: Src Family Kinases (SFKs) have a crucial role in tumor proliferation, survival, and metastasis. NXP900 is a highly selective SFK inhibitor with a novel mechanism of action that locks SFKs in a closed, inhibited conformation, providing sustained suppression of catalytic and non-catalytic functions, which is distinct from other SFK inhibitors like dasatinib. A phase I clinical trial of NXP900 in patients with advanced solid tumors is ongoing. Our preclinical studies showed therapeutic efficacy of NXP900 in cholangiocarcinoma (CCA) through decreased YAP, RAF-MAP and PI3K-AKT signaling. Multiomic profiling (RNA-seq, proteomics, phosphoproteomics) of CCA patient-derived xenografts implicated AKT pathway activation in primary NXP900 resistance. NXP900-resistant CCA cell lines generated via prolonged sublethal dose escalation showed a strong IL13RA2-AKT signature on multiomic analysis. Thus, we hypothesized that IL13RA2-AKT signaling was a mechanism of NXP900 resistance. We aimed to define this mechanism and demonstrate that the combinatorial targeting of IL13RA2 or AKT resensitizes to NXP900 treatment. Methods: HuCCT1 or HuCCT1-Resisant (HuCCT1-R) cells were injected bilaterally into the flanks of NOD/SCID mice and were allowed to grow for 3 months prior to tumor collection and analysis. Tumor engraftment and growth between HuCCT1 and HuCCT1-R groups were compared. To delineate the mechanisms for acquired NXP900 resistance, in-vitro treatment studies were performed using siRNAs targeting IL13RA2 as well as combination treatment with capivasertib, a pan-AKT inhibitor. Results: The HuCCT1-R cell line exhibited a higher rate of tumor engraftment and formed significantly larger tumors compared to the parental HuCCT1 cell line, indicating enhanced tumorigenic potential associated with acquired resistance. Silencing of IL13RA2 in HuCCT1-R cells resulted in pronounced reduction of cell proliferation and partially restored sensitivity to NXP900 treatment. Immunoblot analysis demonstrated a corresponding reduction in phosphorylated AKT (Thr308), consistent with suppression of downstream PI3K-AKT signaling. Furthermore, combination treatment of HuCCT1-R cells with the AKT inhibitor capivasertib, and NXP900 led to a significant increase in cell death and a greater inhibition in cell proliferation compared to either agent alone, indicating enhanced responsiveness and improved therapeutic efficacy. Conclusion: These findings confirm the central role of IL13RA2 signaling and the PI3K-AKT pathway in mediating acquired resistance to NXP900, consistent with our previous multiomics analysis. Importantly, this study identifies combination strategies that may be able to overcome NXP900 resistance, supporting the development of combinatorial approaches to restore therapeutic efficacy in resistant tumors. Citation Format: Shelby K. Yee, Hendrien Kuipers, Danielle M. Carlson, Jack W. Sample, Enis Ozmert, Hidemi Nishi, Erik Jessen, Dong-Gi Mun, Aushinie M. Abeynayake, Jennifer L. Tomlinson, Amro M. Abdelrahman, Nathan W. Werneburg, Binbin Li, Mitesh J. Borad, Mark J. Truty, Sumera I. Ilyas, Gregory J. Gores, Rory L. Smoot. Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7124.
Abstract 1133: Urine cell-free RNA captures tumor-reflective long intergenic noncoding and circular RNA programs in bladder cancer
Lin, Li Hung, Linford, Jessica , Hashmi, Ayesha , Viswanathan, Anushka , Colon, Nathan, Qaium, Faridi , Sheng, John, Orme, Jacob J. , Smith, Zachary L. , Smelser, Woodson , Maher, Christopher A. , Chaudhuri., Aadel A., Chauhan, Pradeep S. , Lin, Li, Alahi, Irfan , Greiner, Lilli , Harris, Peter K , Kim, Eric H. , Chaudhuri, Aadel A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1133-1133

10.1158/1538-7445.am2026-1133 Get It

Abstract Introduction: Long intergenic noncoding RNAs (lincRNAs) and circular (circ) RNAs have been shown to play key roles in carcinogenesis and tumor progression. Urine represents a promising source of tumor-reflective signals shed directly from the urothelial microenvironment in bladder cancer (BC) patients. Here, we evaluate the urine cell-free (cf) RNA transcriptome in a cohort of 50 patients with localized BC. Methods: A total of 50 localized BC patients and 24 healthy adults were enrolled. Pre-operative urine (collected on the day of radical cystectomy) was processed to isolate cfRNA from urine supernatant. Libraries were prepared using an Illumina tagmentation-based RNA enrichment workflow and sequenced to 100M paired-end reads per sample on a NovaSeq X. FASTQ files were concatenated per sample and QC-checked with RNA-SeQC and Samtools. Reads were aligned to GRCh38/hg38 with STAR, and gene counts were generated using Feature Counts. Linear differential expression analysis (DEA) was performed with DESeq2. For discovery we used random halves of TCGA-BLCA and healthy urine cfRNA samples, alongside a second DEA with random halves of urine BC cfRNA vs. controls; overlapping upregulated genes were validated in the remaining samples. For circular (circ) RNAs, annotations from MiOncoCirc were used; junctions with ≥5 supporting reads were retained, and DEA was conducted with edgeR. Results: In this study, the median age was 68 years, and 80% (40/50) were male. Among the cohort, 66% (33/50) had muscle-invasive bladder cancer (MIBC), of whom 54% received neoadjuvant chemotherapy. Differential expression analysis of TCGA-BLCA tumors and BC urine cfRNA, identified 27 genes commonly upregulated, with 23 of the 27 shared genes strikingly being long intergenic noncoding RNAs (lincRNAs). These BC/urine-specific lincRNAs—including LINC00930, LINC01004, DLG5-AS1, APTR, PSORS1C3, and SERPINB9P1—have known roles in proliferation, EMT, metabolism, and immune signaling. Outside of lincRNAs, tumor-reflective coding transcripts in BC/urine were enriched for autophagy, driven by MAP1LC3B2.TCGA-BLCA survival analysis showed that LINC00930 and PSORS1C3 were associated with worse overall survival. Expanding beyond linear RNA sequences, analysis of urine circRNAs from BC patients revealed a strong cancer-specific dysregulation pattern, with 77 circRNAs significantly upregulated compared with healthy controls. Upregulated urine circRNAs arose from host genes involved in BC-relevant pathways, including invasion (DOCK1, ARHGAP5), autophagy/ER stress (VMP1, ERN1), and luminal differentiation (GRHL2, ESRP1). Conclusion: Cell-free RNA profiling reveals a distinct transcriptomic signature including differential lincRNA- and circRNA-driven autophagy, EMT, proliferation, metabolic, differentiation, and immune signaling programs in the urine of bladder cancer patients. Citation Format: Pradeep Chauhan, Li Lin, Irfan Alahi, Jessica Linford, Lilli J. Greiner, Ayesha Hashmi, Anushka Viswanathan, Nathan Colon, Faridi Qaium, Peter K. Harris, John Sheng, Jacob J. Orme, Eric H. Kim, Zachary L. Smith, Woodson Smelser, Christopher A. Maher, Aadel A. Chaudhuri. Urine cell-free RNA captures tumor-reflective long intergenic noncoding and circular RNA programs in bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1133.
Monte Carlo–based optimization of CTV‐to‐PTV margins for image‐guided VMAT prostate radiotherapy
Chen, Quan, Ammar, Ali, Yu, Nathan Y., Zhu, Libing, Vargas, Carlos E., Zhu, Libing , Yu, Nathan Y. , Rong, Yi , Vargas, Carlos E.

Mayo Clinic

Medical Physics | March 31, 2026 | Volume: 53 | Issue: 4 | Pages: No page available

10.1002/mp.70415 | PMID 41912350 Get It

Abstract Background The van Herk margin formula, derived for 3‐D conformal radiotherapy with a uniform 3.2 mm dose penumbra and no intrinsic dose buffer, remains widely used to design CTV‐to‐PTV expansions in contemporary image‐guided prostate radiotherapy. However, coplanar VMAT techniques often feature broader penumbrae and explicit PTV–isodose clearances, potentially violating the assumptions underlying the original formulation and leading to overly conservative margins. Purpose We investigated whether the widely adopted van Herk margin formula overestimates clinical target volume (CTV)‐to‐planning target volume (PTV) expansions for contemporary coplanar volumetric modulated arc therapy (VMAT) prostate treatments. Methods Fifty consecutive intact‐prostate VMAT radiotherapy plans (two coplanar arcs; clinical margins 3 mm, except for 2 mm posterior) were exported. Direction‐specific 90% isodose–to‐PTV gaps and penumbra widths were measured. Candidate anisotropic margins were tested by eroding the PTV to create CTV_eval. Monte‐Carlo simulations combined systematic (Σ) shifts with Gaussian random (σ′) blurring kernels of 0–2 mm were performed. Acceptability criteria of (i) CTV Dmin0.03 cc ≥ 90% Rx in ≥ 90% of simulated scenarios or (ii) population tumor‐control probability (TCP) loss < 1 % were used. Results VMAT plans exhibited intrinsic 90% isodose clearances of 3–5 mm laterally/anteriorly and 1–2 mm superior–inferiorly, while axial‐plane penumbras were up to fivefold broader than van Herk's assumption. With a [0, 0, 2] mm (LR/AP/SI) margin, ≥ 90% of patients maintained Dmin0.03 cc ≥ 90% Rx provided Σ lay within an ellipsoid of [2.0, 1.5, 1.8] mm and σ′ ≤ [1.5, 2.0, 1.5] mm. Under TCP criteria the safe Σ ellipsoid for high‐risk disease was [2.5, 1.9, 2.2] mm, while low‐intermediate risk was even less sensitive. Conclusions For image‐guided coplanar VMAT prostate radiotherapy, an anisotropic [0, 0, 2] mm CTV‐to‐PTV margin is sufficient for target coverage. A modified margin expression that subtracts the measured isodose–to‐PTV gap and uses reduced random‐error coefficients better reflects modern practice.
Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulation
Replogle, John, Marks, Jordan D. , Fernandez, Martin G , Yu, Dahyun , Winters, Elizabeth, Jawahar, Vidhya Maheswari, Deshmukh, Rishi, Sutanto, Renaldo, Kowal, Isabelle, Frankenfield, Ashley M. , Shi, Rachel , Carlomagno, Yari , Jansen-West, Karen, Kopach, Andrii , Ndayambaje, I. Sandra , Qi, Yue Andy, Shantaraman, Ananth, Pozo-Cabanell, Ignacio, Sheth, Udit , Yue, Mei, Duong, Duc, Bennett, David A, Damme, Markus, Boeve, Brad F, Day, Gregory S, Skarnes, William C, Petersen, Ronald C, Josephs, K., Graff-Radford, Neill, Barmada, Sami J. , Zhang, Yongjie, Hao, Ling , DeTure, Michael , Rawlinson, Bailey, Cook, Erica Engelberg, Casey, Monica Castanedes, Perez, Nathan M, Dickson, Dennis, Liu, Yue, Seyfried, Nicholas T., Wingo, Thomas S, Mosalaganti, Shyamal , Petrucelli, Leonard, Ward, Michael E, Ward, Michael E. , Replogle, John Michael , Todd, Tiffany W. , Engelberg-Cook, Erica , Perez, Nathan, Ward, Michael E , Barmada, Sami , Sheth, Udit , Yuan, Hebao , Kowal, Isabelle , Jansen‐West, Karen , Qi, Yue , Shantaraman, Anantharaman , Duong, Duc, Ferguson, Shawn M. , Bennett, David A. , Daμμe, Markus , Day, Gregory S. , Kellman, Benjamin P. , Skarnes, William C. , Petersen, Ronald C. , Graff‐Radford, Neill R. , McDonough, Justin A. , Prudencio, Mercedes , Dickson, Dennis W. , Wingo, Aliza P. , Liu, Yue, Seyfried, Nicholas T. , Wingo, Thomas S , Petrucelli, Leonard

Mayo Clinic

No container title available | March 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.26.714634 | PMID 41929000 Get It

Variants in TMEM106B and GRN , which encode lysosomal proteins, interact through unknown mechanisms to increase the risk of age-related cognitive decline and neurodegeneration. Here, we show that these variants converge on a single molecular intermediate: the cleaved intra-lysosomal fibril core of TMEM106B, a precursor to amyloid fibrils that accumulate in the aging brain. A protein-coding TMEM106B risk variant (p.T185) drives fibril core accumulation by impairing its degradation and GRN risk variants amplify this effect. Mice over-expressing the fibril core develop hallmarks of neurodegeneration, and cryo-electron tomography reveals intra-lysosomal fibrils in cultured neurons, mice, and diseased human brain. In GRN -mutation carriers, in whom fibril burden is greatest, fibrils extrude through ruptured lysosomal membranes. These findings identify intra-lysosomal TMEM106B fibrillization as a convergent neurodegeneration mechanism and potential therapeutic target.
Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Paredes, Anghela Z. , Beckhorn, Catherine B , Fusco, Joseph , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Jensen, Amanda , Dasgupta, Roshni, Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M., Murphy, Andrew J., Piché, Nelson , Le‐Nguyen, Annie, Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Lopez, A. Javier, Mello, Kelsey , Short, Joshua , Petroze, Robin T. , Rajavel, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Fowler, Kathryn , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit, Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G., Barkhordar, Aaron, Austin, Mary, Coakley, Brian A. , Murphy, Joseph T., Pitonak, M., Boehmer, Chloé , Beckhorn, Catherine , Kastenberg, Zachary J , Lautz, Timothy , Brungardt, Joseph G , Murphy, Andrew J , Thompson, Grace R , Glick, Richard D , Seemann, Natashia M , Joshi, Devashish , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Polites, Stephanie F. , Stetson, Alyssa , Lee, William G , Barkhordar, Aaron , Malek, Marcus M , Rinehardt, Hannah , Tracy, Elisabeth T. , Leraas, Harold J. , Hoyt, David , Marchese, Charles R. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Talbot, Lindsay J , Davidoff, Andrew M. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , Mannava, Sindhu V , Castle, Shannon L. , Lopez, Adriana, Rajavel, Shay , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn, Brown, Erin G. , Le, Hau D. , Ahmed, Tamer, Ehrlich, Peter F. , Gorgy, Merit , Kim, Eugene S. , Kahan, Anastasia M , Murphy, Joseph T., Malek, Marcus M.

Mayo Clinic

Pediatric Blood & Cancer | March 27, 2026 | Volume: 73 | Issue: 6 | Pages: No page available

10.1002/1545-5017.70296 | PMID 41889149 Get It

ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed by institutions participating in the Pediatric Surgical Oncology Research Collaborative. Children younger than 21 years old with MRTK diagnosed between 2000 and 2022 were included. Results Sixty‐nine patients were identified with MRTK and met the inclusion criteria. Median age of diagnosis was 10.1 months. Overall survival (OS) at 1, 5, and 10 years was 49%, 32%, and 19%, respectively. Patients with local Stage III disease who underwent upfront resection ( n = 18) compared to those who had delayed resection after NAT ( n = 15) had a similar OS, median OS greater than 60 months versus 14.6 months, respectively; p = 0.396. The surgical timing groups were balanced in terms of the presence of metastasis, length of follow‐up, and tumor characteristics. There was one occurrence of primary intraoperative tumor spill and two occurrences of organ injury in the upfront resection group compared to none in the delayed resection group. Conclusion MRTK carries a poor prognosis despite multimodal treatment. Histologic diagnosis may not be confirmed at presentation, and MRTK cannot be reliably distinguished from Wilms tumor on imaging alone. As overall survival is similar, the decision regarding surgical timing in locally advanced tumors should be individualized based on perceived resectability, balancing the risk of intraoperative complications against the possibility of tumor progression during neoadjuvant therapy.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.
Morphologically Malignant Nodular Fasciitis With COL3A1::USP6 Fusion and aTP53 Mutation
Suchi, Mariko, Yuksel, Selcen S. , Oliveira, Andre M., Schloemer, Nathan J. , Bone, Kathleen M., Lin, Kant YK, Suchi, Mariko , Bone, Kathleen M.

Mayo Clinic

Annals of Plastic Surgery | March 24, 2026 | Volume: 97 | Issue: 1 | Pages: 37-41

10.1097/sap.0000000000004729 | PMID 41874377 Get It

Nodular fasciitis is a rapidly growing soft tissue tumor that typically arises in children and young adults. Histologically, it consists of short, sweeping, and intersecting fascicles of bland-appearing myofibroblasts. The majority of nodular fasciitis lesions harbor rearrangements involving the ubiquitin-specific protease 6 ( USP6 ) gene. Most lesions are benign, with a tendency to regress spontaneously or remain stable following conservative excision. However, rare cases have shown clinically aggressive behavior, including distant metastasis. More recently, morphologic variants with malignant features have also been reported. We present a 20-month-old boy who developed a rapidly enlarging facial mass following blunt trauma. The excised mass revealed a variant of nodular fasciitis displaying marked cellular pleomorphism and frequent atypical mitotic figures. Molecular analysis identified a COL3A1::USP6 fusion and a TP53 Y234C mutation. While the majority of facial lesions referred to plastic surgeons for excision are benign, this case highlights the need for a broad differential diagnosis that includes both benign and potentially malignant entities. It also emphasizes the importance of multidisciplinary evaluation and management in patients with complex and unusual pathologic diagnoses.
932: COORDINATION OF OR MEDICATION PRESCRIBING, PREPARATION AND DELIVERY FOR THORACIC TRANSPLANT PATIENTS
Sonchaiwanich, Alyssa, Lemke, Adley, Brinkman, Nathan, Bernard, Stacy, Lemke, Adley , Brinkman, Nathan , Bernard, Stacy A.

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001185724.46539.1f Get It

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
Abdallah, Nadine, White, Thomas, Heeren, Amanda A., Wildes, Tanya, Marar, Rosalyn, Yee, Claire , Bodily, Anna, Kotajarvi, Brian R., Aug, Sarah, Kapoor, Prashant , Dispenzieri, Angela, Hayman, Suzanne, Dingli, David, Gonsalves, Wilson, Cook, Joselle, Zanwar, Saurabh , Lin, Y., Kourelis, Taxiarchis, Gertz, MA, Warsame, Rahma, Rajkumar, S, LeBrasseur, Nathan, Kumar, Shaji, Weivoda, Megan , Abdallah, Nadine H , Heeren, Amanda, Marar, Rosalyn , Yee, Claire , Kotajarvi, Brian, Buadi, Francis K , Kapoor, Prashant , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Gertz, Morie A , Rajkumar, S Vincent , Sfeir, Jad G , Kumar, Shaji K , Weivoda, Megan , Abdallah, Nadine , Smith, Byron H. , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Hayman, Suzanne, Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Sfeir, Jad , LeBrasseur, Nathan K

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8605152/v1 | PMID 41890848 Get It

Abstract Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.